At 0.8x sales and 1.4x book with a Forward P/E of 8.5, the market is pricing Baxter as a low-expectation turnaround rather than a growth compounder. The absence of a trailing P/E, combined with an Operating Margin of -15.60% and ROIC of -4.20%, signals impaired profitability despite a positive EPS of 21.8 and a projected EPS of -1.75 next year. The Altman Z-Score of 2.2 places the company in a gray zone—neither distressed nor financially robust—while a Piotroski F-Score of 4 confirms mediocre financial health. This is not a pristine balance sheet story, but rather a restructuring case where the 8.5 forward multiple implies the market expects stabilization, not expansion. The stock looks statistically cheap, but the fundamentals justify skepticism rather than screaming mispricing.